In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barnaby Pickering

Reporter

London, UK

Barnaby Pickering lives and works in Yorkshire. Graduating from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.

Latest From Barnaby Pickering

Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

In Vitro Diagnostics Cancer

Dexcom’s G7 Expands Globally After A Long Wait

Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.

Diabetic Care Business Strategies

Novartis Heart Health Catalyst Announces Dual Winners

PocDoc and Lifelight have won the Novartis’ Heart Health Catalyst program and will work on smartphone-based lipid-measuring and clinical vital signs tools for evaluating cardiac health on a population level.

Platform Technologies Financing

Minute Insight: Viagra May Face Stiff US Competition From Futura’s Gel-Based Device

MED3000 works in 10 minutes and will be available over the counter, if approved.

Drug Delivery Technology Commercial

Snapshot: September Highlights

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Rare Diseases Regulation

Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

In Vitro Diagnostics Cancer
See All
UsernamePublicRestriction

Register